Eli Lilly (LLY) Stock Analysis
A structured research starting point for Eli Lilly — price history, key metrics, the questions great investors would ask, and community sentiment. Educational only.
Price Chart
View recent prices as a table
| Date | Close |
|---|---|
| 2026-11-09 | $1411.95 |
| 2026-11-06 | $1354.00 |
| 2026-11-05 | $1364.73 |
| 2026-11-04 | $1417.99 |
| 2026-11-03 | $1409.38 |
| 2026-11-02 | $1410.99 |
| 2026-10-30 | $1417.54 |
| 2026-10-29 | $1373.70 |
| 2026-10-28 | $1288.30 |
| 2026-10-27 | $1281.91 |
Overview
Eli Lilly is a global pharmaceutical company with deep franchises in diabetes, obesity, oncology, immunology, and neuroscience. Its GLP-1 medicines for diabetes and weight management have become a major growth engine.
Pharma moats rest on patents, clinical pipelines, and manufacturing scale. The key debates for investors are the durability of demand, competition in the obesity market, and the valuation premium for high-growth drug pipelines.
Key Metrics at a Glance
Approximate reference figures for education. Always verify against the latest filings before any decision.
Key Dates
How the Masters Would Frame It
Each legendary investor asks different questions. Use these lenses as a structured checklist — not as buy or sell signals.
| Investor | Their lens | Key question they would ask |
|---|---|---|
| Warren Buffett | Durable moat & predictability | How durable are the patents and franchises, and what happens at patent expiry? |
| Peter Lynch | Growth vs. price (PEG) | Does the GLP-1 growth story justify a premium multiple? |
| Howard Marks | Where are we in the cycle? | How much obesity-drug optimism is already priced in? |
| Benjamin Graham | Margin of safety | What protection exists if pipeline trials disappoint or competition intensifies? |
Community & market-attention modules4
Community Sentiment
How does the community feel about this stock right now? Cast your vote.
Value × Sentiment Map
Where this stock sits on two axes: how its price compares to its own 1-year average (cheap ↔ expensive), and how the crowd feels on X right now (bearish ↔ bullish). Value investing rewards looking where the crowd is not.
Could not build the map right now. Please try again later.
7-Day TikTok Buzz
How much this stock has been talked about on TikTok over the past week — daily video count, weighted by engagement.
Bars: daily public TikTok videos mentioning this stock (via TikHub), scaled by engagement. Line: daily closing price (via EODHD) over the same days — see whether chatter leads or follows the price. Delayed and approximate, for information only — not advice.
Social Media Buzz
What X/Twitter is saying about this stock right now — auto-scored bullish vs bearish from recent cashtag posts.
Latest News & Announcements
Recent earnings coverage and market headlines for this stock, synced automatically.
- Hims' Roller Coaster Ride Continues With Surprise Losses, Light Sales And A Guidance Cut
- Hims & Hers Stock Is Falling Ahead of Earnings. What to Expect.
- Eli Lilly, Novo weight-loss drugs to get rare vision loss warning
- Eli Lilly’s Weight-Loss Pill Shows Sleep Apnea Benefits. Can It Gain on Novo?
- Sector Update: Healthcare Stocks Rise Monday Afternoon
- Eli Lilly Stocks Rise 3.40% as Jefferies Sets Street-High $1,700 Target
- FDA requires vision-loss warning on Novo Nordisk and Eli Lilly GLP-1 drugs
- Indices Hunt for Support After Steep Weekly Losses as Volatility Gauge Stays Elevated
Headlines aggregated from public sources via EODHD. For information only, not advice.
Frequently Asked Questions
Is Eli Lilly a good stock to buy?
We do not give buy or sell advice. The useful question is whether Lilly fits your goals and whether the price reflects realistic pipeline outcomes. Use the master frameworks above as a checklist.
What drives Eli Lilly's growth?
In recent years, its GLP-1 medicines for diabetes and obesity, alongside oncology and immunology franchises, have been major growth drivers.
What are the main risks for LLY?
Commonly cited risks include patent cliffs, clinical-trial failures, competition in the obesity market, and a high valuation that prices in strong growth.
How do I value a pharma company like LLY?
Many investors use a DCF on durable cash flows and risk-adjust the pipeline, then test the implied growth with a reverse-DCF. Try our calculators below.
Free email digests when there is new analysis, earnings coverage, and valuation context. No spam.
We respect your privacy. Unsubscribe anytime.Compare With Other Stocks
Related Stocks
Quick Facts
Fast answers to common questions about this stock:
Related Guides & Glossary
Learn the frameworks used on this page:
Not financial advice
This page is an educational research starting point built from public information. It is not investment advice, not a recommendation to buy or sell, and figures may be delayed or approximate. Always do your own research.
Research this company with master frameworks inside the app:
Get the App